What We Should Do To Counteract The Graying Of The Science Profession

The system of federal support for biomedical research is ailing, according to National Institutes of Health director Bernadine Healy. In an interview published in Science (257:312, 1992), she stated that "with the average success rate on applications, now hovering around 25 percent, numerous meritorious research projects are not receiving NIH support.... "Perhaps the most serious long-term problem for biomedical research," she went on, "is that the young seem to be shying away. Fewer scientist

Written byDonald Klein
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

"Perhaps the most serious long-term problem for biomedical research," she went on, "is that the young seem to be shying away. Fewer scientists under the age of 40 are applying for NIH grants and the group under 45 is a fast-shrinking component of our total talent base. In immediate terms, talented postdocs are becoming harder to find, and young people trained in research are turning to other careers."

Apparently, becoming an independent investigator by virtue of current NIH funding practices has become too difficult and chancy for younger people. Some might contend that the problem lies in the nature of peer review--that it unfairly favors experienced scientists. However, I feel that attempts to improve the quality of peer review are beside the point: It makes sense, doesn't it, that since relatively few applications are being funded, peer reviews must rely on past productivity, thereby constricting the funding available for untried ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies